A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma

INTRODUCTION: High-dose interleukin-2 (HD IL-2) and pembrolizumab are each approved as single agents by the U.S. F.D.A. for the treatment of metastatic melanoma. There is limited data using the agents concurrently. The objectives of this study were to characterize the safety profile of IL-2 in combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Silk, Ann W., Curti, Brendan, Bryan, Jennifer, Saunders, Tracie, Shih, Weichung, Kane, Michael P., Hannon, Phoebe, Fountain, Christopher, Felcher, Jessica, Zloza, Andrew, Kaufman, Howard L., Mehnert, Janice M., McDermott, David F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949373/
https://www.ncbi.nlm.nih.gov/pubmed/36845705
http://dx.doi.org/10.3389/fonc.2023.1108341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949373/
https://www.ncbi.nlm.nih.gov/pubmed/36845705
http://dx.doi.org/10.3389/fonc.2023.1108341

Ejemplares similares